Atezolizumab (programmed cell death-ligand 1 antibody)-induced inflammation of actinic keratosis: A case report.
SAGE Open Med Case Rep
; 10: 2050313X221131863, 2022.
Article
em En
| MEDLINE
| ID: mdl-36388634
ABSTRACT
Atezolizumab is a programmed cell death-ligand 1 antibody that modulates the immune system response and has shown great promise in treating malignancies. Cutaneous toxicities from immune checkpoint inhibitors are the most commonly reported immune-related adverse events, although toxicities related to immunotherapy are still being characterized. Herein, we present a novel case of inflamed actinic keratoses in a patient after receiving atezolizumab therapy that resolved without requirement of dose adjustment or discontinuation of treatment.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Idioma:
En
Revista:
SAGE Open Med Case Rep
Ano de publicação:
2022
Tipo de documento:
Article
País de afiliação:
Estados Unidos